Jazz Pharmaceuticals Completes $820 Million Upfront Acquisition of Actio Biosciences
MT newswire2026/09/15 14:16Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
10:16 AM EDT, 09/15/2026 (MT Newswires) -- Jazz Pharmaceuticals (JAZZ) has completed its acquisition of privately held Actio Biosciences for $820 million upfront, the company said Tuesday. The acquisition adds ABS-1230, a clinical-stage investigational therapy for KCNT1-related epilepsy, to Jazz Pharmaceuticals' pipeline. ABS-1230 is an oral, small-molecule KCNT1 inhibitor being developed for KCNT1-related epilepsy. Price: 244.75, Change: -1.12, Percent Change: -0.46
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
LCI Industries' Lippert Unit Chooses ketteQ for Supply Chain Planning Platform
MT newswire•2026/09/15 15:19
Ducommun Investor Day Focus Likely to Be Margin Expansion, M&A Deals, RBC Says
MT newswire•2026/09/15 15:19
Update: Market Chatter: Banco Santander, BBVA, Deutsche Bank Working on Several Significant Risk Transfer Deals
MT newswire•2026/09/15 15:19
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
MT newswire•2026/09/15 15:18
